Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
7
×
europe blog main
7
×
life sciences
national blog main
europe top stories
boston blog main
boston top stories
clinical trials
eli lilly
fda
san francisco blog main
cancer
indiana blog main
indiana top stories
national top stories
san francisco top stories
cancer drugs
national
new york blog main
new york top stories
abbvie
amgen
blueprint medicines
boehringer ingelheim
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
europe
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
What
drug
7
×
fda
approval
cancer
medicine
carries
designed
marketing
medicines
patients
weight
acquisitions
address
alkermes
amgen
amgen’s
antipsychotic
approves
benefits
bid
biggest
bio
biotech
black
blueprint
boehringer
build
buy
caveats
ceo
certain
clinic
commonly
companies
company’s
daniel
debut
developed
diabetes
diamond
Language
unset
7
×
Current search:
drug
×
unset
×
biotech
×
" europe blog main "
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning